Merck & Co., Inc. (NYSE:MRK) Shares Sold by Park National Corp OH
Merck & Co., Inc. (NYSE:MRK) Shares Sold by Park National Corp OH
Park National Corp OH trimmed its stake in shares of Merck & Co., Inc. (NYSE:MRK – Get Rating) by 8.4% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 102,229 shares of the company's stock after selling 9,382 shares during the quarter. Park National Corp OH's holdings in Merck & Co., Inc. were worth $9,320,000 at the end of the most recent quarter.
据Park National Corp OH最近提交给美国证券交易委员会(Securities and Exchange Commission，简称：美国证券交易委员会)的文件显示，该公司在第二季度减持了8.4%的默克公司股票。该机构投资者在本季度出售了9,382股后，持有该公司股票102,229股。截至最近一个季度末，Park National Corp OH持有的默克公司股份价值9,320,000美元。
Several other institutional investors and hedge funds have also recently bought and sold shares of MRK. Norges Bank acquired a new position in shares of Merck & Co., Inc. during the 4th quarter worth about $1,823,028,000. BlackRock Inc. boosted its position in shares of Merck & Co., Inc. by 5.5% during the 4th quarter. BlackRock Inc. now owns 198,224,263 shares of the company's stock worth $15,191,909,000 after acquiring an additional 10,326,974 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Merck & Co., Inc. by 12.7% during the 4th quarter. Geode Capital Management LLC now owns 48,153,283 shares of the company's stock worth $3,682,009,000 after acquiring an additional 5,409,154 shares in the last quarter. Renaissance Technologies LLC boosted its position in shares of Merck & Co., Inc. by 2,671.4% during the 1st quarter. Renaissance Technologies LLC now owns 5,099,334 shares of the company's stock worth $418,400,000 after acquiring an additional 4,915,334 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of Merck & Co., Inc. by 2.3% during the 1st quarter. Vanguard Group Inc. now owns 216,096,057 shares of the company's stock worth $17,730,682,000 after acquiring an additional 4,893,526 shares in the last quarter. 73.33% of the stock is owned by institutional investors and hedge funds.
其他几家机构投资者和对冲基金最近也买卖了MRK的股票。挪威银行在第四季度增持了价值约1,823,028,000美元的默克公司股票。贝莱德在第四季度将其在默克公司的股票持仓量提高了5.5%。贝莱德股份有限公司在上个季度增持了10,326,974股后，现在持有198,224,263股该公司股票，价值15,191,909,000美元。Geode Capital Management LLC在第四季度将其在默克公司(Merck&Co.，Inc.)的股票头寸增加了12.7%。Geode Capital Management LLC在上个季度增持了5,409,154股后，现在拥有48,153,283股该公司股票，价值3,682,009,000美元。复兴科技有限责任公司在第一季度将其在默克公司的股票头寸增加了2,671.4%。复兴科技有限责任公司在上个季度增持了4,915,334股后，现在拥有5,099,334股该公司股票，价值418,400,000美元。最后，先锋集团(Vanguard Group Inc.)在第一季度将其在默克公司(Merck&Co.，Inc.)的股票头寸增加了2.3%。先锋集团目前持有216,096,057股该公司股票，价值17,730,682,000美元，上个季度又购入了4,893,526股。73.33%的股票由机构投资者和对冲基金持有。
Analyst Ratings Changes
分析师评级发生变化
Several research analysts have recently issued reports on the company. Atlantic Securities upped their price objective on Merck & Co., Inc. from $105.00 to $110.00 and gave the stock an "overweight" rating in a research report on Wednesday, July 13th. Cowen boosted their target price on Merck & Co., Inc. from $95.00 to $102.00 and gave the company a "market perform" rating in a report on Monday, June 27th. Berenberg Bank raised Merck & Co., Inc. from a "hold" rating to a "buy" rating and boosted their target price for the company from $95.00 to $100.00 in a report on Wednesday. Cowen boosted their target price on Merck & Co., Inc. from $95.00 to $102.00 and gave the company a "market perform" rating in a report on Monday, June 27th. Finally, Daiwa Capital Markets raised Merck & Co., Inc. from a "neutral" rating to a "buy" rating and boosted their target price for the company from $89.00 to $102.00 in a report on Wednesday, July 6th. Seven investment analysts have rated the stock with a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $98.28.
几位研究分析师最近发布了关于该公司的报告。大西洋证券在7月13日星期三的一份研究报告中将默克公司的目标价从105.00美元上调至110.00美元，并给予该股“增持”评级。考恩在6月27日周一的一份报告中将默克公司的目标价从95美元上调至102.00美元，并给予该公司“市场表现”评级。贝伦伯格银行在周三的一份报告中将默克公司的评级从持有上调至买入，并将该公司的目标价从95美元上调至100.00美元。考恩在6月27日周一的一份报告中将默克公司的目标价从95美元上调至102.00美元，并给予该公司“市场表现”评级。最后，大和资本市场在7月6日周三的一份报告中将默克公司的评级从中性上调至买入，并将该公司的目标价从89美元上调至102.00美元。7名投资分析师对该股的评级为持有，11名分析师给出了买入评级，两名分析师给出了强烈的买入评级。根据MarketBeat.com的数据，该股目前的平均评级为“中等买入”，平均目标价为98.28美元。
Merck & Co., Inc. Stock Performance
默克公司股票表现
Merck & Co., Inc. (NYSE:MRK – Get Rating) last issued its earnings results on Thursday, July 28th. The company reported $1.87 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.67 by $0.20. The business had revenue of $14.59 billion during the quarter, compared to the consensus estimate of $13.85 billion. Merck & Co., Inc. had a return on equity of 48.45% and a net margin of 29.00%. The company's revenue for the quarter was up 28.0% on a year-over-year basis. During the same period in the prior year, the business posted $1.31 EPS. On average, equities analysts forecast that Merck & Co., Inc. will post 7.33 EPS for the current year.
默克公司(纽约证券交易所代码：MRK-GET评级)最近一次发布收益报告是在7月28日星期四。该公司公布本季度每股收益(EPS)为1.87美元，高于分析师普遍预期的1.67美元和0.20美元。该业务本季度营收为145.9亿美元，而市场普遍预期为138.5亿美元。默克公司的股本回报率为48.45%，净利润率为29.00%。该公司本季度营收同比增长28.0%。去年同期，该业务的每股收益为1.31美元。股票分析师平均预测，默克公司本年度每股收益将达到7.33欧元。
Merck & Co., Inc. Announces Dividend
默克公司宣布分红
The company also recently declared a quarterly dividend, which will be paid on Friday, October 7th. Investors of record on Thursday, September 15th will be issued a $0.69 dividend. This represents a $2.76 dividend on an annualized basis and a dividend yield of 3.15%. The ex-dividend date of this dividend is Wednesday, September 14th. Merck & Co., Inc.'s dividend payout ratio is currently 42.27%.
该公司最近还宣布了季度股息，将于10月7日(星期五)支付。9月15日(星期四)登记在册的投资者将获得0.69美元的股息。这意味着年化股息为2.76美元，股息收益率为3.15%。本次股息除息日为9月14日星期三。默克公司目前的股息支付率为42.27%。
Merck & Co., Inc. Profile
默克公司简介
(Get Rating)
(获取评级)
Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.
默克公司是一家全球性的医疗保健公司。它通过两个部门运作，制药和动物健康。制药部门提供肿瘤学、医院急性护理、免疫学、神经科学、病毒学、心血管和糖尿病等领域的人类健康药物产品，以及疫苗产品，如预防性儿科、青少年和成人疫苗。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on Merck & Co., Inc. (MRK)
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- 3 Banks Worth Considering For Q4
- Is There a Cure for What is Ailing Teladoc Stock?
- MarketBeat: Week in Review 9/12 – 9/16
- No One Told These 3 Stocks It's a Down Week
- 免费获取StockNews.com关于默克公司的研究报告(MRK)
- 股市：红海中的三座强国
- 第四季度值得考虑的3家银行
- 有什么办法可以治愈Teladoc股票的问题吗？
- MarketBeat：回顾一周9/12-9/16
- 没有人告诉这三只股票这是下跌的一周
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Get Rating).
想看看还有哪些对冲基金持有MRK吗？访问HoldingsChannel.com获取默克公司(NYSE：MRK-GET Rating)的最新13F文件和内幕交易信息。
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
每天收到默克公司的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对默克公司和相关公司的最新新闻和分析师评级的每日简要摘要。